The Biden administration’s May 5 about-face on the proposed TRIPS waiver of intellectual property (IP) protections for COVID-19-related medical products is not playing well with U.S. industry, EU trading partners and others concerned about the long-term unintended consequences.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amt, My01, Renovacare, Viome.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Everest, Lyndra, Merck & Co., RDIF.
Once again, the World Trade Organization (WTO) postponed a decision on a temporary intellectual property (IP) waiver for COVID-19 vaccines and other related medical products.
The rocky first quarter for public biopharmaceutical companies continued into April as the BioWorld Biopharmaceutical index remained flat for the period in contrast to the general market, with the Dow Jones Industrial Average growing by more than 2%. Weighing on the sector has been softer than expected earnings in the period among the top tier companies.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Autogen, Axim Biotechnologies, Cell Projects, Centogene, CN Bio, Eagle Genomics, Empowered Diagnostics, Exagen, Femselect, Fluxergy, Gene Group Holdings, Genostics, Heartflow, Isohelix, Konica Minolta, Lina Medical USA, Medaxiom, Nvoq, Oncimmune, Perahealth, Rxbio, Sientra, Spectrum Solutions, Stagezero, United Health Products, US Medical Innovations, Vtnc.
RSS
